The earnings call indicates increased R&D expenses and declining cash reserves, with no new partnerships secured. The competitive market and economic uncertainties pose risks, and management's vague responses on partnerships and trial timelines add to concerns. Despite some promising trials, the lack of concrete progress or guidance, combined with financial challenges, suggests a negative stock reaction.